Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins
1 other identifier
interventional
200
1 country
1
Brief Summary
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 23, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2020
CompletedFirst Submitted
Initial submission to the registry
December 19, 2020
CompletedFirst Posted
Study publicly available on registry
December 31, 2020
CompletedDecember 31, 2020
December 1, 2020
5 months
December 19, 2020
December 30, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
7 days
Secondary Outcomes (3)
Hospital stay
15 days
Oxygen demand
7-15 days
Viral load
7-15 days
Study Arms (4)
Control
NO INTERVENTIONTocilizumab
EXPERIMENTALRemdesivir
EXPERIMENTALStandard Treatment
ACTIVE COMPARATORInterventions
Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Eligibility Criteria
You may qualify if:
- Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy
You may not qualify if:
- Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The University of Lahore
Lahore, Punjab Province, 54000, Pakistan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Arif Malik, PhD
University of Lahore
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
December 19, 2020
First Posted
December 31, 2020
Study Start
July 23, 2020
Primary Completion
December 10, 2020
Study Completion
December 10, 2020
Last Updated
December 31, 2020
Record last verified: 2020-12